Predicting response and survival in chemotherapy-treated triple-negative breast cancer

Abstract

Background:In this study, we evaluated the ability of gene expression profiles to predict chemotherapy response and survival in triple-negative breast cancer (TNBC).Methods:Gene expression and clinical–pathological data were evaluated in five independent cohorts, including three randomised clinical trials for a total of 1055 patients with TNBC, basal-like disease (BLBC) or both. Previously defined intrinsic molecular subtype and a proliferation signature were determined and tested. Each signature was tested using multivariable logistic regression models (for pCR (pathological complete response)) and Cox models (for survival). Within TNBC, interactions between each signature and the basal-like subtype (vs other subtypes) for predicting either pCR or survival were investigated.Results:Within TNBC, all intrinsic subtypes were identified but BLBC predominated (55–81%). Significant associations between genomic signatures and response and survival after chemotherapy were only identified within BLBC and not within TNBC as a whole. In particular, high expression of a previously identified proliferation signature, or low expression of the luminal A signature, was found independently associated with pCR and improved survival following chemotherapy across different cohorts. Significant interaction tests were only obtained between each signature and the BLBC subtype for prediction of chemotherapy response or survival.Conclusions:The proliferation signature predicts response and improved survival after chemotherapy, but only within BLBC. This highlights the clinical implications of TNBC heterogeneity, and suggests that future clinical trials focused on this phenotypic subtype should consider stratifying patients as having BLBC or not.

An In Vivo Functional Screen Identifies JNK Signaling As a Modulator of Chemotherapeutic Response in Breast Cancer

“…As proliferation rate is known to be associated with chemotherapy response (32), it was critical to confirm that the resistance mediated by JNK knockdown or inhibition was independent of its cytostatic effect. Compared with the effects observed in subconfluent cells (Fig.…”

Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy

“…29,54 In a clinical research of 1055 patients with TNBC, BLBC or both, only when TNBC can be stratified into BLBC subtype could patients be identified with notably better response after chemotherapy. 55 Previous studies show that BLBC harbors the hallmarks of BRCAness. 21 In conclusion, BLBC is an important consideration for prediction of platinum efficacy in TNBC.…”

Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay

“…In practice, Luminal A tumors have lower ROR scores than other subtypes. Previous studies have shown that the sensitivity of a tumor to chemotherapeutic agents is associated with its proliferative state (22)(23)(24). Thus, it is not surprising that ROR score, as an inclusive measure of a tumor's proliferative potential, can predict those tumors that would be more sensitive to chemotherapeutic agents.…”